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Impairment of functional integrity of the vasculature is not changed in patients starting abacavir
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Purpose of the study
In order to explore a possible pathogenetic mechanism of abacavir (ABC) cardiovascular toxicity, we assess the impact of beginning the drug on endothelial function via assessment of brachial artery diameter (BAD) and flowmediated dilation (FMD).
Methods
Cross-sectional observational study that included all consecutive HIV-infected patients seen at a metabolic clinic who had BAD and FMD evaluation before and 9 months after beginning ABC as a component of a new drug regimen.
Summary of results
There were no overt metabolic, virological or antiretroviral drug-related factors associated with BAD and FMD change over time among patients starting ABC. (Figure 1) 
Conclusion
Change in impairment of functional integrity of the vasculature is not an associated factor related with ABC use. Cardiovascular disease risk among HIV-infected HAARTexperienced persons is likely governed by complex pathophysiologic and treatment factors. 
